Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT-EXT: Belatacept in Extended Criteria Donor Kidney Transplant
NCT00114777Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2005
- Primary completion
- May 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of belatacept in kidney transplant rejection (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Percentage of Participants Who Survived With a Graft at 12 months and Percentage of Participants With a Measured GFR <60 mL/Min or Decrease >=10 mL/Min at 12 months. Started Feb 2005; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00114777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114777.